title: [Experience with radiofrequency ablation in the treatment of unresectable pelvic recurrence of rectal cancer].
abstract: More than half of colorectal cancers are located in the rectum, and the number of such cancers is increasing. In Hungary colorectal cancers are diagnosed predominantly in advanced stages. In the last five years 736 patients with colorectal cancer were operated on at our Department, with the following stage distribution: Dukes A 10%, BI 10%, B2 31%, C 36% and D 13%. The local recurrence rate is decreasing since the introduction of total mesorectal excision and preoperative radiation. Effective treatment options are however poor for unresectable pelvic recurrences. Chemo- and radiotherapy have severe limitations in this advanced stage cancer. In recent years there are a few publications on the minimal-invasive radiofrequency tumour ablation (RFTA) technique, which is an effective treatment for primary and metastatic liver carcinomas and is a new palliative for the local treatment of pelvic recurrence. The aim of this study was to assess the response to treatment using ultrasound-guided radiofrequency ablation in two patients with unresectable pelvic recurrent rectal cancer.
authors: Országos Onkológiai Intézet, Altalános es Mellkassebészeti Osztály, Budapest. matraidok@freemail.hu
authors: Zoltán
authors: Z
authors: Mátrai
authors: István
authors: I
authors: Fehér
authors: Gábor
authors: G
authors: Péley
authors: Ferenc
authors: F
authors: Rényi Vámos
authors: Emil
authors: E
authors: Farkas
authors: Zoltán
authors: Z
authors: Sulyok
authors: Tibor
authors: T
authors: Kovács
authors: István
authors: I
authors: Köves
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D017115:Catheter Ablation / Q000295:instrumentation / Q000379:methods; D005260:Female; D006801:Humans; D010386:Pelvic Neoplasms / Q000276:immunology / Q000556:secondary* / Q000628:therapy*; D012004:Rectal Neoplasms / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen